Affluent Medical SA (AFME) AI Stock Analysis

• Market Cap: €62.13M
• Dividend Yield: N/A
• Average Volume (3M): 13.32K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.57
• Revenue Growth: N/A
• EPS Growth: 22.21%
• Country: FR
• Employees: 66
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.14
• Shares Outstanding: 39,348,022
• 10 Day Avg. Volume: 7,085
• 30 Day Avg. Volume: 13,320
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €3.80
• Price Target Upside: 146.75% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 46 Neutral
• Price Target: €1.50 ▼(-2.60% Downside)

Affluent Medical SA's stock score is primarily impacted by its financial performance challenges, including negative profitability and cash flow inefficiencies. Despite strong revenue growth, the company's operational struggles weigh heavily on its overall score. Technical analysis shows bullish momentum, but the overbought RSI suggests caution. Valuation metrics further highlight the company's financial difficulties, with a negative P/E ratio and no dividend yield.

Affluent Medical SA Business Overview & Revenue Model

Company Description

Affluent Medical SA (AFME) is a medical technology company focused on developing innovative solutions for the treatment of various health conditions, particularly in the cardiovascular and urology sectors. The company's core products include advanced medical devices and therapeutic solutions designed to improve patient outcomes and enhance healthcare efficiency. AFME is committed to leveraging cutting-edge technology and scientific research to address unmet medical needs, positioning itself as a key player in the global healthcare landscape.

How the Company Makes Money

Affluent Medical SA generates revenue primarily through the sale of its medical devices and therapeutic solutions. The company’s revenue model includes direct sales to hospitals, clinics, and healthcare providers, as well as partnerships with distributors and other medical organizations for broader market reach. Key revenue streams consist of product sales, recurring revenues from consumables and maintenance services, and potential licensing fees from partnerships with other medical technology firms. Significant partnerships with healthcare institutions and research organizations further contribute to the company's earnings by facilitating clinical trials, product development, and market penetration.

Affluent Medical SA Financial Statement Overview

Summary

Affluent Medical SA exhibits strong revenue growth but faces significant profitability and cash flow challenges. The company maintains a moderate debt level, but negative returns on equity and cash flow inefficiencies highlight ongoing financial struggles. While there are signs of improvement in cash flow, the company needs to address its operational inefficiencies to achieve sustainable profitability.

Income Statement

Affluent Medical SA has shown significant revenue growth of 217.99% in the latest year, indicating strong top-line expansion. However, the company struggles with profitability, as evidenced by negative gross profit and net profit margins of -58.18% and -357.92%, respectively. The EBIT and EBITDA margins are also deeply negative, highlighting ongoing operational challenges.

Balance Sheet

The company's debt-to-equity ratio of 0.54 suggests moderate leverage, which is relatively stable compared to previous years. However, the return on equity is negative at -48.69%, indicating that the company is not generating positive returns for shareholders. The equity ratio stands at 49.75%, reflecting a balanced capital structure but with ongoing profitability issues.

Cash Flow

Affluent Medical SA's free cash flow has grown by 52.89%, showing improvement in cash generation. However, the operating cash flow to net income ratio is negative, indicating that the company is not converting its earnings into cash effectively. The free cash flow to net income ratio is slightly positive at 1.01, suggesting some level of cash flow stability despite overall financial challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.12M	1.22M	1.34M	1.45M	824.00K
Gross Profit	-2.40M	-1.20M	-1.10M	-1.07M	-2.28M
EBITDA	-13.44M	-13.34M	-13.21M	-10.89M	-10.47M
Net Income	-14.74M	-15.65M	-15.23M	-14.82M	-14.32M
Balance Sheet
Total Assets	60.86M	56.62M	60.02M	70.03M	64.83M
Cash, Cash Equivalents and Short-Term Investments	6.62M	1.66M	2.58M	11.41M	5.65M
Total Debt	16.33M	17.13M	17.73M	19.75M	20.78M
Total Liabilities	30.59M	25.15M	26.19M	26.50M	29.54M
Stockholders Equity	30.27M	31.47M	33.83M	43.53M	35.29M
Cash Flow
Free Cash Flow	-11.47M	-12.24M	-11.23M	-12.70M	-9.24M
Operating Cash Flow	-11.32M	-12.05M	-11.08M	-12.36M	-8.94M
Investing Cash Flow	-480.00K	-184.00K	-146.00K	-160.00K	-304.00K
Financing Cash Flow	11.37M	11.32M	2.40M	18.28M	12.76M

Affluent Medical SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.54
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:AFME, the sentiment is Positive. The current price of 1.54 is below the 20-day moving average (MA) of 1.57, above the 50-day MA of 1.44, and above the 200-day MA of 1.39, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 51.27 is Neutral, neither overbought nor oversold. The STOCH value of 56.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:AFME.

Affluent Medical SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AFME	46 Neutral	€62.13M	―	-47.78%	―	―	22.21%
ALMDT	44 Neutral	103.27M	-2.16	74.31%	―	3.25%	-2.07%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%